McKesson stock hits all-time high at 867.9 USD

McKesson stock has reached an all-time high, hitting 867.9 USD, showcasing the company’s robust performance in the market. According to InvestingPro data, the stock is trading slightly below its Fair Value, suggesting potential for further growth despite the recent rally. Over the past year, McKesson has experienced a remarkable 39.05% increase in its stock price, reflecting strong investor confidence and positive market sentiment. The healthcare provider’s year-to-date return is even more impressive at 49.54%, while maintaining a low volatility profile with a beta of just 0.39. This milestone highlights McKesson’s successful strategies and resilience in navigating the current economic landscape. Management has been aggressively buying back shares while maintaining a 32-year streak of dividend payments, with 15.49% dividend growth in the last twelve months. As the company continues to build on its achievements, market analysts and investors will be keenly observing its future trajectory and performance, with analyst price targets ranging from $760 to $1000.InvestingPro identifies 17 additional investment tips for McKesson, including its financial health rating of "GREAT" and detailed revenue growth metrics. Access McKesson’s comprehensive Pro Research Report, part of the 1,400+ US equities covered with in-depth analysis on the platform.

In other recent news, McKesson Corporation reported its fiscal Q2 2026 earnings, highlighting a significant increase in earnings per share (EPS) while slightly missing revenue forecasts. The company achieved an EPS of $9.86, surpassing the expected $9.04, although revenue reached $103 billion, just under the anticipated $104.15 billion. In light of these results, Leerink Partners raised its price target for McKesson to $965, maintaining an Outperform rating. The firm described McKesson’s recent performance as "an incredibly strong distributor quarter," with all major segments exceeding both firm and consensus expectations. Additionally, Evercore ISI increased its price target to $1,000, also maintaining an Outperform rating. Evercore highlighted the North American Pharmaceutical segment’s expected growth, projecting approximately 7% core adjusted operating income growth for fiscal year 2026. The segment is anticipated to grow by 4-5% in the second half of the year, following a 7-11% growth in the first half. These developments reflect ongoing positive sentiment among analysts towards McKesson’s financial performance and future prospects.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.